Key clinical point: Fremanezumab therapy led to significant reductions in patient-reported headache frequency and migraine pain intensity in patients with migraine.
Main finding: After fremanezumab initiation, the mean number of headache days/month reduced from 22.24 days preindex to 8.24 days postindex ( P < .0001) and the mean visual analog scale pain score from 5.47 preindex to 4.51 postindex ( P = .014).
Study details: This was a retrospective, observational cohort study including 172 adult patients with migraine who received fremanezumab (index event), had ≥6 months of enrollment/treatment history preindex and ≥1 month postindex along with no pregnancy event during the study.
Disclosures: The study was sponsored by Teva Branded Pharmaceutical Products R&D, Inc. The lead author received research support from and served as a consultant for various organizations including Teva. Some of the authors are current/former employees of Teva.
Source: McAllister P et al. J Headache Pain. 2021;22:156 (Dec 20). Doi: 10.1186/s10194-021-01358-9.